Xi Chen, Xinyu Wei, Peizhuo Yao, Yanbin Liu, Haitao Guan, Huafeng Kang, Di Liu, Yan Diao, Xiaobin Ma, Weili Min, Changyou Shan, Yang Zhao, Fang Zhao, Yuanyuan Chen, Dong Xiao, Qing She, Youhuai Liu, Yinbin Zhang, Shuqun Zhang
BACKGROUND: The combination of neoadjuvant chemotherapy and anti-angiogenesis therapy for patients with triple-negative breast cancer (TNBC) remains inadequately supported by evidence. We conducted a single-arm, open-label, multicenter, phase II trial to evaluate the efficacy and toxicity of anlotinib plus epirubicin and cyclophosphamide followed by paclitaxel in patients with IIB to IIIA stage TNBC. METHODS: Newly diagnosed patients received epirubicin at 90 mg/m2 and cyclophosphamide at 600 mg/m2 followed by docetaxel at 100 mg/m2 (21 days per cycle; total of 4 cycles), along with oral anlotinib (12 mg qd, d1-14; 21 days per cycle; total of 4 cycles)...
March 8, 2024: Clinical Breast Cancer